About beyond air inc - XAIR
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air, Beyond Cancer segments, and NeuroNos. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.
XAIR At a Glance
Beyond Air, Inc.
900 Stewart Avenue
Garden City, New York 11530
| Phone | 1-516-665-8200 | Revenue | 7.68M | |
| Industry | Medical Specialties | Net Income | -33,249,000.00 | |
| Sector | Health Technology | 2026 Sales Growth | 107.26% | |
| Fiscal Year-end | 03 / 2027 | Employees | 54 | |
| View SEC Filings |
XAIR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.746 |
| Price to Book Ratio | 1.329 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.47 |
| Enterprise Value to Sales | 1.554 |
| Total Debt to Enterprise Value | 1.959 |
XAIR Efficiency
| Revenue/Employee | 142,203.704 |
| Income Per Employee | -615,722.222 |
| Receivables Turnover | 6.448 |
| Total Asset Turnover | 0.235 |
XAIR Liquidity
| Current Ratio | 3.804 |
| Quick Ratio | 3.588 |
| Cash Ratio | 2.651 |
XAIR Profitability
| Gross Margin | 3.282 |
| Operating Margin | -378.226 |
| Pretax Margin | -447.116 |
| Net Margin | -432.986 |
| Return on Assets | -101.606 |
| Return on Equity | -337.399 |
| Return on Total Capital | -112.67 |
| Return on Invested Capital | -125.34 |
XAIR Capital Structure
| Total Debt to Total Equity | 381.717 |
| Total Debt to Total Capital | 79.241 |
| Total Debt to Total Assets | 66.084 |
| Long-Term Debt to Equity | 369.931 |
| Long-Term Debt to Total Capital | 76.794 |